Clinical trial
D2C7 for Adult Patients With Recurrent Malignant Glioma
NCT02303678 · Darell Bigner, Other · Completed
Key facts
| NCT number | NCT02303678 |
|---|---|
| Title | D2C7 for Adult Patients With Recurrent Malignant Glioma |
| Official title | Phase I Single-Center, Dose Escalation Study of D2C7-IT Administered Intratumorally Via Convection-Enhanced Delivery for Adult Patients With Recurrent Malignant Glioma |
| Lead sponsor | Darell Bigner, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Malignant Glioma, Brain Tumor, Recurrent |
| Intervention type | Drug |
| Interventions | D2C7-IT |
| Enrollment | 81 |
| Start date | May 5, 2015 |
| Primary completion | May 9, 2019 |
| Completion | Mar 25, 2024 |
| First posted | Dec 1, 2014 |
| Last update posted | Apr 2, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: